A Multi-center, Double-blind, Placebo-controlled, Randomized Study to Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes Treated With Differing Baseline Diabetes Therapies.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Canakinumab (Primary)
- Indications Glucose intolerance; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
- 03 Aug 2011 Actual end date (August 2010) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History